1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. https://doi.org/10.1002/ijc.29210 https://pubmed.ncbi.nlm.nih.gov/25220842 
2. Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T. Cancer burden in slovenia with the time trends analysis. Radiol Oncol. 2017;51(1):47-55. https://doi.org/10.1515/raon-2017-0008 https://pubmed.ncbi.nlm.nih.gov/28265232 
3. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28(1):92-8. https://doi.org/10.1200/JCO.2008.19.9844 https://pubmed.ncbi.nlm.nih.gov/19933921 
4. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23(29):7350-60. https://doi.org/10.1200/JCO.2005.03.3845 https://pubmed.ncbi.nlm.nih.gov/16145060 
5. Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer. 2017;8(16):3131-41. https://doi.org/10.7150/jca.18457 https://pubmed.ncbi.nlm.nih.gov/29158785 
6. Cope LM, Fackler MJ, Lopez-Bujanda Z, Wolff AC, Visvanathan K, Gray JW, et al. Do breast cancer cell lines provide a relevant model of the patient tumor methylome? PLoS One. 2014;9(8):e105545. https://doi.org/10.1371/journal.pone.0105545 https://pubmed.ncbi.nlm.nih.gov/25157401 
7. Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer. Breast Dis. 2010;32(1-2):35-48. https://doi.org/doi: 10.1371/journal.pone.0105545 https://pubmed.ncbi.nlm.nih.gov/25157401 
8. Ellis IO, Collins L, Ichihara S, MacGrogan G. Invasive carcinoma of no special type. In: Lakhani SR, Elis IO, Schnitt SJ, Tan PH, Vijver MJ, eds. WHO classification of Tumours of the Breast. Lyon: IARC; 2012. 
9. Lakhani SR, Rakha E, Simpson PT. Special subtypes. In: Lakhani SR, Elis IO, Schnitt SJ, Tan PH, Vijver MJ, eds. WHO classification of tumours of the breast. Lyon: IARC; 2012. 
10. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52. https://doi.org/10.1038/35021093 https://pubmed.ncbi.nlm.nih.gov/10963602 
11. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869-74. https://doi.org/10.1073/pnas.191367098 https://pubmed.ncbi.nlm.nih.gov/11553815 
12. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418-23. https://doi.org/10.1073/pnas.0932692100 https://pubmed.ncbi.nlm.nih.gov/12829800 
13. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736-50. https://doi.org/10.1093/jnci/djp082 https://pubmed.ncbi.nlm.nih.gov/19436038 
14. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68(9):3108-14. https://doi.org/10.1158/0008-5472.CAN-07-5644 https://pubmed.ncbi.nlm.nih.gov/18451135 
15. Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5(10):2929-43. https://pubmed.ncbi.nlm.nih.gov/26693050 
16. Hole S, Pedersen AM, Hansen SK, Lundqvist J, Yde CW, Lykkesfeldt AE. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. Int J Oncol. 2015;46(4):1481-90. https://doi.org/10.3892/ijo.2015.2850 https://pubmed.ncbi.nlm.nih.gov/25625755 
17. Holen I, Speirs V, Morrissey B, Blyth K. In vivo models in breast cancer research: progress, challenges and future directions. Dis Model Mech. 2017;10(4):359-71. https://doi.org/10.1242/dmm.028274 https://pubmed.ncbi.nlm.nih.gov/28381598 
18. Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13(4):215. https://doi.org/10.1186/bcr2889 https://pubmed.ncbi.nlm.nih.gov/21884641 
19. Greely HT, Cho MK. The Henrietta Lacks legacy grows. EMBO Rep. 2013;14(10):849. https://doi.org/10.1038/embor.2013.148 https://pubmed.ncbi.nlm.nih.gov/24030280 
20. Lasfargues EY, Ozzello L. Cultivation of human breast carcinomas. J Natl Cancer Inst. 1958;21(6):1131-47. https://pubmed.ncbi.nlm.nih.gov/13611537 
21. Amadori D, Bertoni L, Flamigni A, Savini S, De Giovanni C, Casanova S, et al. Establishment and characterization of a new cell line from primary human breast carcinoma. Breast Cancer Res Treat. 1993;28(3):251-60. https://doi.org/10.1007/BF00666586 https://pubmed.ncbi.nlm.nih.gov/8018954 
22. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer. 1998;78(6):766-74. https://doi.org/10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L https://pubmed.ncbi.nlm.nih.gov/9833771 
23. Lee AV, Oesterreich S, Davidson NE. MCF-7 cells—changing the course of breast cancer research and care for 45 years. J Natl Cancer Inst. 2015;107(7):djv073-073. https://doi.org/10.1093/jnci/djv073 https://pubmed.ncbi.nlm.nih.gov/25828948 
24. International Cell Line Authentication Committee. Naming a Cell Line - ver. 1.6. 2015[cited 2018 Apr 18]. Available from: http://iclac.org/wp-content/uploads/Naming-a-Cell-Line_v1_6.pdf 
25. Riaz M, van Jaarsveld MT, Hollestelle A, Prager-van der Smissen WJ, Heine AA, Boersma AW, et al. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res. 2013;15(2):R33-33. https://doi.org/10.1186/bcr3415 https://pubmed.ncbi.nlm.nih.gov/23601657 
26. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321(3):288-300. https://doi.org/10.1001/jama.2018.19323 https://pubmed.ncbi.nlm.nih.gov/30667505 
27. Bertucci F, Borie N, Ginestier C, Groulet A, Charafe-Jauffret E, Adélaide J, et al. Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene. 2004;23(14):2564-75. https://doi.org/10.1038/sj.onc.1207361 https://pubmed.ncbi.nlm.nih.gov/14743203 
28. Sahlberg KK, Hongisto V, Edgren H, Mäkelä R, Hellström K, Due EU, et al. The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. Mol Oncol. 2013;7(3):392-401. https://doi.org/10.1016/j.molonc.2012.10.012 https://pubmed.ncbi.nlm.nih.gov/23253899 
29. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10(6):515-27. https://doi.org/10.1016/j.ccr.2006.10.008 https://pubmed.ncbi.nlm.nih.gov/17157791 
30. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One. 2009;4(7):e6146. https://doi.org/10.1371/journal.pone.0006146 https://pubmed.ncbi.nlm.nih.gov/19582160 
31. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adélaide J, Cervera N, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2006;25(15):2273-84. https://doi.org/10.1038/sj.onc.1209254 https://pubmed.ncbi.nlm.nih.gov/16288205 
32. Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. 2011;3(12):a005058. https://doi.org/10.1101/cshperspect.a005058 https://pubmed.ncbi.nlm.nih.gov/21917992 
33. Dai X, Xiang L, Li T, Bai Z. Cancer hallmarks, biomarkers and breast cancer molecular subtypes. J Cancer. 2016;7(10):1281-94. https://doi.org/10.7150/jca.13141 https://pubmed.ncbi.nlm.nih.gov/27390604 
34. Wang B, Elledge SJ. Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci USA. 2007;104(52):20759-63. https://doi.org/10.1073/pnas.0710061104 https://pubmed.ncbi.nlm.nih.gov/18077395 
35. Gradisnik L, Trapecar M, Rupnik MS, Velnar T. HUIEC, Human intestinal epithelial cell line with differentiated properties: process of isolation and characterisation. Wien Klin Wochenschr. 2015;127(S5):S204-9. https://doi.org/10.1007/s00508-015-0771-1 https://pubmed.ncbi.nlm.nih.gov/25821058 
36. Naranda J, Gradišnik L, Gorenjak M, Vogrin M, Maver U. Isolation and characterization of human articular chondrocytes from surgical waste after total knee arthroplasty (TKA). PeerJ. 2017;5:e3079. https://doi.org/10.7717/peerj.3079 https://pubmed.ncbi.nlm.nih.gov/28344902 
37. Lacroix M, Haibe-Kains B, Hennuy B, Laes JF, Lallemand F, Gonze I, et al. Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes. Oncol Rep. 2004;12(4):701-7. https://doi.org/10.3892/or.12.4.701 https://pubmed.ncbi.nlm.nih.gov/15375488 
38. Hiscox S, Baruha B, Smith C, Bellerby R, Goddard L, Jordan N, et al. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer. 2012;12(1):458. https://doi.org/10.1186/1471-2407-12-458 https://pubmed.ncbi.nlm.nih.gov/23039365 
39. Larramendy ML, Lushnikova T, Björkqvist AM, Wistuba II, Virmani AK, Shivapurkar N, et al. Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines. Cancer Genet Cytogenet. 2000;119(2):132-8. https://doi.org/10.1016/S0165-4608(99)00226-5 https://pubmed.ncbi.nlm.nih.gov/10867149 
40. Nestor CE, Ottaviano R, Reinhardt D, Cruickshanks HA, Mjoseng HK, McPherson RC, et al. Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems. Genome Biol. 2015;16(1):11. https://doi.org/10.1186/s13059-014-0576-y https://pubmed.ncbi.nlm.nih.gov/25648825 
41. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene. 2002;21(35):5462-82. https://doi.org/10.1038/sj.onc.1205606 https://pubmed.ncbi.nlm.nih.gov/12154408 
42. Kapałczyńska M, Kolenda T, Przybyła W, Zajączkowska M, Teresiak A, Filas V, et al. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci. 2018;14(14):910-9. https://doi.org/10.5114/aoms.2016.63743 https://pubmed.ncbi.nlm.nih.gov/30002710 
43. Hsieh C-H, Chen Y-D, Huang S-F, Wang H-M, Wu M-H. The effect of primary cancer cell culture models on the results of drug chemosensitivity assays: the application of perfusion microbioreactor system as cell culture vessel. Biomed Res Int. 2015;2015:470283. https://doi.org/10.1155/2015/470283 https://pubmed.ncbi.nlm.nih.gov/25654105 
44. Bulysheva AA, Bowlin GL, Petrova SP, Yeudall WA. Enhanced chemoresistance of squamous carcinoma cells grown in 3D cryogenic electrospun scaffolds. Biomed Mater. 2013;8(5):055009. https://doi.org/10.1088/1748-6041/8/5/055009 https://pubmed.ncbi.nlm.nih.gov/24057893 
45. Fackler MJ, Lopez Bujanda Z, Umbricht C, Teo WW, Cho S, Zhang Z, et al. Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res. 2014;74(8):2160-70. https://doi.org/10.1158/0008-5472.CAN-13-3392 https://pubmed.ncbi.nlm.nih.gov/24737128 
46. Christgen M, Lehmann U. MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing. Cancer Biol Ther. 2007;6(9):1355-7. https://doi.org/10.4161/cbt.6.9.4624 https://pubmed.ncbi.nlm.nih.gov/17786032 
47. Dvořánková B, Szabo P, Lacina L, Kodet O, Matoušková E, Smetana K. Fibroblasts prepared from different types of malignant tumors stimulate expression of luminal marker keratin 8 in the EM-G3 breast cancer cell line. Histochem Cell Biol. 2012;137(5):679-85. https://doi.org/10.1007/s00418-012-0918-3 https://pubmed.ncbi.nlm.nih.gov/22270320 
48. Hoarau-Véchot J, Rafii A, Touboul C, Pasquier J. Halfway between 2D and ANIMAL MODELS: Are 3D cultures the ideal tool to study cancer-microenvironment interactions? Int J Mol Sci. 2018;19(1):181. https://doi.org/10.3390/ijms19010181 https://pubmed.ncbi.nlm.nih.gov/29346265 
49. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100(18):10393-8. https://doi.org/10.1073/pnas.1732912100 https://pubmed.ncbi.nlm.nih.gov/12917485 
50. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355(6):560-9. https://doi.org/10.1056/NEJMoa052933 https://pubmed.ncbi.nlm.nih.gov/16899776 
51. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-67. https://doi.org/10.1172/JCI45014 https://pubmed.ncbi.nlm.nih.gov/21633166 
52. Hynds RE, Vladimirou E, Janes SM. The secret lives of cancer cell lines. Dis Model Mech. 2018;11(11):dmm037366. https://doi.org/10.1242/dmm.037366 https://pubmed.ncbi.nlm.nih.gov/30459183 
53. Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, et al. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol. 2012;127(1):241-8. https://doi.org/10.1016/j.ygyno.2012.06.017 https://pubmed.ncbi.nlm.nih.gov/22710073 
54. Gillet J-P, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst. 2013;105(7):452-8. https://doi.org/10.1093/jnci/djt007 https://pubmed.ncbi.nlm.nih.gov/23434901 
55. Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 2014;74(9):2377-84. https://doi.org/10.1158/0008-5472.CAN-13-2971 https://pubmed.ncbi.nlm.nih.gov/24717177 
56. Fusenig NE, Capes-Davis A, Bianchini F, Sundell S, Lichter P. The need for a worldwide consensus for cell line authentication: experience implementing a mandatory requirement at the International Journal of Cancer. PLoS Biol. 2017;15(4):e2001438. https://doi.org/10.1371/journal.pbio.2001438 https://pubmed.ncbi.nlm.nih.gov/28414712 
